Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Palliative Care for Haematological Malignancies
NCT03800095Phase 3Unknown
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Mar 2019
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Quality of Life (FACT-An Scale) at 6 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03800095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800095.